Ensuring Quality of Product Throughout Gene Therapy Production, Manufacture and Scale-Up

Chair

Nathalie Clement, Vice President, Vector Development, Translational Gene Therapies, Siren Biotechnology

1pm Presentation Title: Building and Maintaining Quality in a New Gene Therapy Manufacturing Facility

Sarah Thomas, Senior Vice President, Quality, REGENXBIO

1.15pm Presentation Title: Navigating Complexities of Viral Vector Production for Gene Therapies

• Learn about standardizing LVV and AAV production to streamline the path to GMP
• Explore comprehensive analytical panels that can accelerate your clinical journey

Francesca Bellintani, MSAT Director, AGC Biologics

1.30pm Presentation

Alex Bloom, Chief Technology Officer, AviadoBio

1.45pm Presentation Title: Exploring the Future of Scalable Gene Therapies

• Exploration of the next several years of gene therapy development, looking at the evolution of the gene therapy manufacturing platform.
• Evaluation of who of the industry is pursuing stable producer cell lines, how are they pursuing, and what are the biggest hurdles.
• A look at how CMOs can play a critical role in this industry evolution, with commentary on the potential risks and rewards for engaging with these organizations.

Peter Walters, Fellow, Advanced Therapies, CRB Group